Domain | Prescribers | Dispensers | Total | 95% CI | Chi-square | P. value |
---|---|---|---|---|---|---|
N = 72 | N = 47 | N = 119 | ||||
n (%) | n (%) | n (%) | ||||
HP recognized Artesunate-sulphadoxine/pyrimethamine (ASP) as the first-line treatment | 67 | 43 | 110 | 87.6-97.2 | 0.332 | 0.847 |
93.1 | 91.5 | 92.4 | ||||
HP stated the recommended dose for ASP in mg correctly | 22 | 13 | 35 | 21.9-38 | 1.787 | 0.618 |
32.8 | 29.5 | 29.7 | ||||
HP recognized how ASP is taken correctly | 44 | 24 | 68 | 49.0-66.8 | 1.172 | 0.279 |
61.1 | 51.1 | 57.1 | ||||
HP recognized Artemether + lumefantrine (AL) as the second-line treatment | 48 | 24 | 72 | 51.7-69.3 | 7.084 | 0.069 |
66.7 | 51.1 | 60.5 | ||||
HP stated the recommended dose for AL in mg correctly | 26 | 16 | 42 | 26.7-43.9 | 1.800 | 0.407 |
36.1 | 34 | 35.3 | ||||
HP recognized how AL is taken correctly. | 46 | 24 | 70 | 50.0-67.6 | 1.932 | 0.381 |
63.9 | 51.1 | 58.8 | ||||
HP recognized quinine as the third-line treatment | 60 | 42 | 102 | 79.4-92.2 | 4.201 | 0.122 |
83.3 | 89.4 | 85.7 | ||||
HP stated the recommended dose for oral quinine correctly | 56 | 18 | 74 | 53.5-71.0 | 20.732 | 0.000 |
77.8 | 38.3 | 62.2 | ||||
HP recognized the main indication for administering injectable quinine in malaria patients | 43 | 32 | 75 | 54.3-71.1 | 1.358 | 0.715 |
59.7 | 68.1 | 63 | ||||
ACT knowledgable* | 16 | 10 | 26 | 14.6-29.4 | 0.026 | 1 |
22.5 | 21.3 | 22 |